BL-1020

From Wikipedia, the free encyclopedia

Jump to: navigation, search
BL-1020
Perphenazine gamma-aminobutyrate.svg
Systematic (IUPAC) name
2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate
Identifiers
CAS Number 751477-01-7
PubChem CID 11203271
ChemSpider 9378339
UNII K1WO7H97QZ YesY
ChEMBL CHEMBL1187646
Chemical data
Formula C25H33ClN4O2S
Molar mass 489.08 g·mol−1

BL-1020 (perphenazine gamma-aminobutyrate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia, it's an ester of GABA and perphenazine, and pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials.[1] In March 2013, it went into the II/III trial phase.[2] It has been introduced by BioLineRx, a biopharmaceutical development company.

References[edit]

  1. ^ Geffen, Y; Keefe, R; Rabinowitz, J; Anand, R; Davidson, M (September 2012). "Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.". The Journal of Clinical Psychiatry 73 (9): e1168–74. doi:10.4088/jcp.12m07642. PMID 23059159. 
  2. ^ Biolinerx (Jan 7, 2013). "BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug during week of March 18, 2013". Biolinerx.